Antipsychotic and mood stabilizer receipt for Veterans Affairs patients with PTSD: A national investigation.
- 1 March 2026
- journal article
- Published by American Psychological Association (APA) in Psychological Trauma: Theory, Research, Practice, and Policy
- Vol. 18 (3) , 638-649
Abstract
Treatment guidelines recommend only a few medications for the treatment of posttraumatic stress disorder (PTSD). There is substantial guideline-nonconcordant treatment for individuals with PTSD, including antipsychotics and mood stabilizers, which have potentially serious adverse side effects. As part of health system monitoring, we examined patient and clinical factors that may be associated with prescribing these medications among Veterans Health Administration (VHA) patients diagnosed with PTSD and without diagnosed comorbid bipolar or psychotic disorders. The study cohort included all VHA patients with PTSD diagnoses in fiscal year 2019 who did not have comorbid diagnoses of schizophrenia, psychotic spectrum disorders, bipolar disorder, or major depressive disorder with psychotic features in fiscal year 2019 or the prior two fiscal years (N = 122,292). Logistic regressions assessed demographic (e.g., age, race) and clinical (e.g., psychiatric diagnosis, health care engagement) factors associated with antipsychotic and mood stabilizer prescription receipt. 11.9% of the cohort received an antipsychotic, the strongest predictors of which were the presence of a suicide risk flag (adjusted odds ratio [aOR] = 1.57) and benzodiazepine prescription (aOR = 1.79). 12.4% of the cohort received a mood stabilizer, the strongest predictors of which were a service-connected disability above 70% (aOR = 1.56) and a comorbid personality disorder diagnosis (aOR = 1.76). VHA patients with PTSD who have psychiatric comorbidity and receive multiple psychiatric medications were more likely to receive guideline-nonconcordant mood stabilizers and antipsychotics. Additional work is needed to better understand the impact of these prescribing practices to help providers balance the risks and benefits of these medication combinations. (PsycInfo Database Record (c) 2026 APA, all rights reserved).Keywords
Funding Information
- U.S. Department of Veterans Affairs
This publication has 30 references indexed in Scilit:
- PTSD Symptom Trajectories in Disaster Volunteers: The Role of Self‐Efficacy, Social Acknowledgement, and Tasks Carried OutJournal of Traumatic Stress, 2016
- The Posttraumatic Stress Disorder Checklist for DSM‐5 (PCL‐5): Development and Initial Psychometric EvaluationJournal of Traumatic Stress, 2015
- Antipsychotic Prescriptions in Iraq and Afghanistan Veterans With Posttraumatic Stress Disorder in Department of Veterans Affairs Healthcare, 2007–2012The Journal of Clinical Psychiatry, 2015
- The Relationship Between Emotion Dysregulation and Impulsive Aggression in Veterans With Posttraumatic Stress Disorder SymptomsJournal of Interpersonal Violence, 2015
- Patient and Facility Characteristics Associated With Benzodiazepine Prescribing for Veterans With PTSDPsychiatric Services, 2013
- Concordance Between Psychotropic Prescribing for Veterans With PTSD and Clinical Practice GuidelinesPsychiatric Services, 2012
- Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSDJAMA, 2011
- Treatment Challenges Associated with Comorbid Substance Use and Posttraumatic Stress Disorder: Clinicians' PerspectivesThe American Journal on Addictions, 2009
- Pharmacologic Treatment of Posttraumatic Stress Disorder Among Privately Insured AmericansPsychiatric Services, 2008
- Comorbidity Measures for Use with Administrative DataMedical Care, 1998